Amersham Health As

Ohr Pharmaceutical Inc.

Ge Healthcare As

Thomas Jefferson University

Ge Healthcare Limited

Amersham Plc

Depymed, Inc.

Combimab, Inc.

Henry Raphael Wolfe

Michael McLane

Halldis Hellebust

Christopher Black

Inez Ruiz-White

Fahar Merchant

Rosemina Merchant

Harry Storflor

Geir Stokke

W Lee Maloy

Alan Cuthbertson

Reinhard Ebner

Scott A Waldman

Robert A Snow

Magne Solbakken

Anthony Eamon Storey

Stephanie Schulz

Jason Park

Paul Mark Henrichs

Marivi Mendizabal

Steven Blair Coffey

Edward R Bacon

Vinay Chandrakant Desai

Sudhakar Kasina

Oskar Axellson

Giovanni Mario Pitari

Hakan Malmgren

Tore Gjorsvik

Wilhelm Lubbe

Anna Rydbeck

Mark Dixon

Sudakar Kasina

Anthony Eamon Amersham Health Plc Storey

Edward Richard Bacon

Marivi Amersham Health Plc Mendizabal

Alan Amersham Health As Cuthbertson

This application is directed to the use of aminosteroid compounds for the selective inhibition of the enzyme PTP1B in a mammal for the treatment of diabetes.

Aminosteroids for the treatment of a PTP1B associated disease

This application is directed to the use of steroid compounds for the selective inhibition of the enzyme PTP1B in a mammal for the treatment of diabetes.

Method for treating diabetes

Therapeutic peptides having guanylyl cyclase C agonist activity are disclosed. The therapeutic peptides are analogues of theSTa peptide with non-natural amino acid, isosteric or D-amino acid substituents. The therapeutic peptides are useful in the treatment of chronic ideopathic constipation, inflammatory bowel disease, and other diseases. Pharmaceutical compositions comprising the therapeutic peptides are also disclosed.

Therapeutic peptides

Proliferation of colorectal, gastric and esophageal cancer cells is inhibited by administering ST receptor ligand. The number of ST receptor molecules on the surface of a colorectal cell or metastasized colorectal cancer cell are increased by administering an ST receptor ligand such that ligand comes into contact with an ST receptor on the surface of the colorectal cell. Pharmaceutical compositions comprise sterile, pyrogen free ST receptor ligand and a pharmaceutically acceptable carrier or diluent. Metastasized colorectal cancer is treated or imaged by increasing the number of ST receptor molecules on the surface of a metastasized colorectal cancer cell and then administering a pharmaceutical composition containing components that target the ST receptor for delivery of a therapeutic agent or imaging agent. Methods of detecting metastasized colorectal cancer are disclosed. Methods of delivering active compounds to a colorectal cell in an individual are disclosed.

Use of GCC ligands

A peptide-chelate conjugate with affinity for the ST receptor is disclosed, wherein the chelate is tetradentate. The peptide-chelate conjugate of the invention may be labelled with a radiometal to provide a metal complex. A radiopharmaceutical composition comprising the metal complex is provided. which is suitable for the diagnostic imaging of colorectal cancer. Also provided for in the invention is a kit for the preparation of the radiopharmaceutical preparation.

Peptide-chelate conjugates

The present invention provides a method of purifying diphtheria toxin comprising (1) fermenting a microorganism strain capable of producing diphtheria toxin using glucose as a carbon source, said method comprising adding glucose to a growing culture whereby the addition of glucose maintains microorganism growth effective to support diphtheria toxin production; and (2) purifying the diphtheria toxin from the culture by contacting a toxin containing preparation derived therefrom with an ion exchange matrix, eluting a fraction containing the toxin, applying the eluate to a hydrophobic matrix, and eluting a fraction containing the toxin.

Process for production of diphtheria toxin

The present invention provides a method of purifying diphtheria toxin comprising (1) fermenting a microorganism strain capable of producing diphtheria toxin using glucose as a carbon source, the method comprising adding glucose to a growing culture whereby the addition of glucose maintains microorganism growth effective to support diphtheria toxin production; and(2) purifying the diphtheria toxin from the culture by contacting a toxin containing preparation derived therefrom with an ion exchange matrix, eluting a fraction containing the toxin, applying the eluate to a hydrophobic matrix, and eluting a fraction containing the toxin.

Process for production diphtheria toxin

A medical or surgical device or tool that is designed to be implanted or inserted inside the human or mammalian body, having at least part of its surface coated whereby the ultrasound visibility of said device or tool in vivo is enhanced, wherein the coating comprises one or more of the following: (i) a matrix material containing a plurality of contrast enhancing elements; (ii) magnesium; (iii) a liquid or polymer which alters its ultrasound imaging properties upon elevating the temperature from ambient to physiological temperature; (iv) a liquid or polymer which alters its ultrasound imaging properties as a result of a change in pH; (v) an essentially non-polymeric bio-compatible compound which forms a discontinuous coating. Preferably the device or tool is a radioactive source for use in brachytherapy, and in particular a radioactive seed.

Medical tools and devices with improved ultrasound visibility

The present invention provides a method of purifying diphtheria toxin comprising (1) fermenting a microorganism strain capable of producing diphtheria toxin using glucose as a carbon source, the method comprising adding glucose to a growing culture whereby the addition of glucose maintains microorganism growth effective to support diphtheria toxin production; and (2) purifying the diphtheria toxin from the culture by contacting a toxin containing preparation derived therefrom with an ion exchange matrix, eluting a fraction containing the toxin, applying the eluate to a hydrophobic matrix, and eluting a fraction containing the toxin.

Novel membrane-forming amphiphilic lipopeptides comprising one or more peptide moieties containing 2-50 aminoacyl residues and one or more hydrocarbon chains containing 5-50 carbon atoms. Such lipopeptides may be used in the formation of stabilized gas microbubble dispersions suitable for use as diagnostic and/or therapeutic agents, for example as ultrasound contrast agents.

Lipopeptide stabilized microbubbles as diagnostic/therapeutic agents

The invention relates inter alia to a method of generating information from an animate human or non-human animal body which method comprises: administering to said body a physiologically tolerable material capable of absorbing, scattering or emitting light at a wavelength in the range 300 to 1300 nm; subjecting at least a portion of said body to ultrasound irradiation; detecting light in the wavelength range 300 to 1300 nm from said portion of said body; and manipulating the detected light to generate said information.

Use of acousto-optical and sonoluminescene contrast agents

Growing community of inventors

Glenmoore, PA, United States of America

Henry Raphael Wolfe